Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 1
2021 pubmed 25 citations

A network of core and subtype-specific gene expression programs in myositis.

Amici. David R DR; Pinal-Fernandez. Iago I; Christopher-Stine. Lisa L; Mammen. Andrew L AL; Mendillo. Marc L ML

Key Findings

  • Myositis muscles show increased genes for regeneration, inflammation, and neutrophil activity, and decreased genes for certain muscle proteins, mitochondria, and the humanin peptide.
  • Different myositis subtypes have unique gene signatures, like interferon signaling in dermatomyositis and vasculogenesis in inclusion body myositis.
  • The gene network can be used by AI to classify patients, and many dysregulated genes are poorly studied, offering new therapeutic possibilities.

Practical Outcomes

  • The main takeaway for biohackers is that humanin levels appear reduced in myositis, but the paper does not provide dosage or protocol guidance. It highlights many potential drug targets, yet none are ready for self‑experimentation. For now, the findings are more useful for researchers than for direct longevity or performance interventions.

Summary

Researchers mapped gene activity in muscle biopsies from people with different types of myositis and found many patterns, including that a version of the anti‑death peptide humanin is lower in these patients. While the study points to many possible drug targets, it doesn’t give direct advice on using humanin or other interventions for health optimization.

Abstract

Myositis comprises a heterogeneous group of skeletal muscle disorders which converge on chronic muscle inflammation and weakness. Our understanding of myositis pathogenesis is limited, and many myositis patients lack effective therapies. Using muscle biopsy transcriptome profiles from 119 myositis patients (spanning major clinical and serological disease subtypes) and 20 normal controls, we generated a co-expression network of 8101 dynamically regulated transcripts. This network organized the myositis transcriptome into a map of gene expression modules representing interrelated biological processes and disease signatures. Universally myositis-upregulated network modules included muscle regeneration, specific cytokine signatures, the acute phase response, and neutrophil degranulation. Universally myositis-suppressed pathways included a specific subset of myofilaments, the mitochondrial envelope, and nuclear isoforms of the anti-apoptotic humanin protein. Myositis subtype-specific modules included type 1 interferon signaling and titin (dermatomyositis), RNA processing (antisynthetase syndrome), and vasculogenesis (inclusion body myositis). Importantly, therapies exist to target influential proteins in many myositis-dysregulated modules, and nearly all modules contained understudied proteins and non-coding RNAs - many of which were extraordinarily dysregulated in myositis and may represent novel therapeutic targets. Finally, we apply our network to patient classification, finding that a deep learning algorithm trained on patient-level network "images" successfully assigned patients to clinical groups and further into molecular subclusters. Altogether, we provide a global resource to probe and contextualize differential gene expression in myositis.

Study Information

Provider

pubmed

Year

2021

Date

2021-09-09T00:00:00.000Z

DOI

10.1007/s00401-021-02365-5

Citations

25

References

43